NVAX logo

NOVAVAX INC

NVAXNASDAQ
🏆 #2018 by market capEarnings Nov 5US Equity
$10.46▲ $0.15 (+1.45%)
Market closed · at close
🔔
Track NVAX
Get earnings, price moves & breaking news on Telegram
Track
24h▲ 1.4%
7d▲ 7.9%
14d▼ 7.0%
30d▼ 3.2%
ytd▲ 55.4%
1y▲ 24.2%
🏦Market Cap
$1.73B
Small Cap
📈Revenue Growth (YoY)
64.7%
High Growth
📊Gross Margin
77.8%
High
💵FCF Margin
-10.5%
Thin
⚖️P/S Ratio
4.2x
Fair
Otter Score
80
Strong

Trading Snapshot

Day Range
$10.21 – $10.59
52-Week Range
$6.20 – $13.39
Volume (shares)
197,411
Avg Volume (shares)
—
Shares Outstanding
164.9M
Next Earnings
2026-11-05

Fundamentals Snapshot

Annual Revenue
$1.12B
Last Q Revenue
$57M
P/E Ratio
-6.9
P/S Ratio
4.2x
EPS (TTM)
$-1.51
Dividend Yield
0.00%
Dilution (1yr)
+8.0%
NVAX logo

NOVAVAX INC

NVAX
Financial Trends
RevenueThe total money the company brought in from sales, before subtracting any costs.
$1.1B▲ +64.7% YoY
Gross MarginOf every $1 of sales, how much is left after the direct cost of making the product/service. Higher = more efficient.
93.7%▲ +33.3% YoY
Operating IncomeProfit from the core business after operating costs, but before interest and taxes. Negative means the core business isn’t profitable yet.
$563M▼ −326.3% YoY
Free Cash FlowCash left over after running the business and paying for equipment/capex. Negative means the company is burning cash.
−$250M▲ +149.4% YoY
Shares OutstandingHow many shares exist. Rising means the company is issuing more shares, which dilutes (shrinks) each existing owner’s slice.
173.1M▲ +8.0% YoY
Net CashCash minus total debt. Positive = more cash than debt (financially strong); negative = more debt than cash (net debt).
−$8M▼ −$308M YoY
StockOtter · stockotter.space

About NOVAVAX INC

Novavax, Inc. is a biotechnology firm dedicated to discovering, developing, and commercializing vaccines aimed at preventing serious infectious diseases and addressing critical health needs. The company's diverse pipeline includes NVX-CoV2373, a coronavirus vaccine candidate currently undergoing two Phase III trials, one Phase IIb, and one Phase I/II trial. Also featured is NanoFlu, a nanoparticle-based seasonal quadrivalent influenza vaccine in Phase 3 clinical trials. Furthermore, Novavax is advancing ResVax, a respiratory syncytial virus (RSV) fusion (F) protein nanoparticle vaccine, which is in Phase II clinical trials for adults aged 60 and older, and in Phase I for pediatric use. The company holds a collaboration agreement with Takeda Pharmaceutical Company Limited for the development, manufacturing, and commercialization of its COVID-19 vaccine candidate, NVX-CoV2373. Established in 1987, Novavax, Inc. is headquartered in Gaithersburg, Maryland.

🦦

Otter Score Breakdown

How it's scoredFive components, each rated 1–5★ and equally weighted (20%), averaged to a 0–100 score:💎 Quality — gross margin🚀 Growth — revenue YoY⚖️ Valuation — P/S ratio⚡ Momentum — 30-day price change💧 Dilution — 1-yr share issuance (buybacks score higher)
💎Quality★★★★★
🚀Growth★★★★★
⚖️Valuation★★★★★
⚡Momentum★★★★★
💧Dilution★★★★★
Overall Score
Strong
80/100

Analyst Ratings

ⓘ
Consensus
Buy
15 analysts
Strong Buy4
Buy6
Hold2
Sell2
Strong Sell1
Ratings as of Oct 2026

Latest News & Updates

News unavailable.